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Introduction. The process of starting a new treatment on an oncologic patient who is going to receive Radiotherapy, supposes
many different tasks and people involved. We organized our Department by a written “task-ﬂow” by the computerized software
ARIA®, taking into account all the different stages, person by person, and task by task.
Objective. To optimize the time since the treatment request arrives till the patient starts Radiotherapy.
Methods. Our work stations have a computerized software (ARIA®, Varian®), in which all the timetable of the different workers
(RadiationOncologists, Radiophysics, RadiationTherapists,Nurses) are able to continuously be aware of all thedifferent steps that
the patient treatment needs to be prepared to start.Wedescribe step by step the different tasks andpeople requiredwith a code. In
capital letters (the task required) e.g.: SIMULATIONCT. Underlinedword (the responsible of the task) e.g.: Therapist, and the arrow
sign (the destination of the task) e.g.: FIRST DOCTOR VISIT: inform Radiation Oncologist/patient notiﬁcation (Therapist) Radiation
Oncologist SIMULATIONCT (Therapist) RadiationOncologist/Therapist SIMULATIONTASKS: importing theCT images/contouring
the OARs (Therapist) Therapist ONCOLOGISTs CONTOURING: GTV/s, CTV/s, PTV/s (Therapist) Radiation Oncologist PLANNING
TASKS (Radiation Oncologist) Radiophysics TREATMENT EVALUATION: HDV/constraints/isodoses (Radiophysics) Radiophysics
Radiation Oncologist TREATMENT VERIFICATION (Radiophysics) Radiophysics TREATMENT SIGNATURE (Radiophysics – Radia-
tion Oncologist) Radiophysics – Radiation Oncologist DATE OF START: inform Radiation Oncologist/patient notiﬁcation (Physic
Department) Therapist/DHX/Radiation Oncologist NEW START: timetable DHX (Therapist/DHX) Radiophysics/Radiation Oncolo-
gist/DHX.
Results. With this method we have seen a more efﬁcient task-ﬂow, in terms of time used since the treatment request arrives to
our Department till the patient starts Radiotherapy.
Conclusion. We conclude that using our software available in our Department, the whole process which requires a very good
coordination between all the members involved.
http://dx.doi.org/10.1016/j.rpor.2013.03.386
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Introduction. Cancer patients often suffer pain, depression, constipation and other symptoms that may impact their quality of
life (QOL). Effective strategies are needed to improve patients QOL.
Objectives. To evaluate QOL (using EQ-5D health questionnaire); pain relief (Brief Pain Inventory – BPI) and bowel function (Bowel
Function Index – BFI) in cancer patients treated in radiation oncology services. Parameterswere evaluated in thewhole population
and subgroups based on the opioid treatments.
Methods. Observational prospective study, 3 months of follow up. Cancer patients with moderate-severe pain (NRS≥4), given
their written consent. Interim subanalysis of 686 patients included in radiation-oncology services, out of 2245 included in both
medical and radiation-oncology services.
Results. Patients with ECOG 0–1: 74%. Age 63±11 years. Most prevalent primary tumor: head and neck (30%). Metastatic cancer
57%. 62% of patients received chemotherapy, 91% radiation. Pain related to metastasis in 46% of patients: patients with problems
in daily activities 79% and with anxiety/depression 73%. 85% of patients received step 3 opioids. Evolution (401 ﬁnalized patients
at cut-off): QOL (EQ-5D index: 0 death-1 best health status) improved from 0.7 to 0.4 (p<0.001). Signiﬁcant improvement of pain
in the four BPI ratings of intensity (worst, least, average and right now: p<0.001). Considering opioid treatment maintained along
the study: outcomes of oxycodone/naloxone group (OXN) were signiﬁcantly favorable to OXN vs other opioids /= OXN (OP). – QOL
(EQ-5D index change): OXN 0.3 vs OP 0.04 (p<0.01). – Greater pain relief in the 4 four ratings of intensity better for OXN; p<0.01.
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Average pain relief: OXN −4; OP −2,5; (p<0.01). – Both clinically and signiﬁcantly favorable bowel function change, in patients
treated with OXN −19.5 vs OP +6.5 (p<0.01).
Conclusions. Cancer patients treated with opioids signiﬁcantly improve their QOL. Maintained opioid treatment with OXN shows
signiﬁcant improvements in QOL, pain relief and bowel function.
http://dx.doi.org/10.1016/j.rpor.2013.03.387
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Introduction. Laryngeal plasmacytomas are very uncommon and few cases are described. We present a patient with multiple
myeloma who has been diagnosed with thyroid cartilage plasmocytoma.
Case. 74 year-old man diagnosed in 2004 of a solitary vertebral plasmacytoma treated with external beam radiotherapy at D5 level.
In 2009, multiple plasmocytomas evidenced along vertebral column. New irradiation was desestimated because of the previous
treatment. Was treated by arthrodesis (D2–D7). A new progression in 2010 was treated with corticoids. He was diagnosed of an
IgAl oligosecreator myeloma and started melfalan-bortezomib-prednisone therapy, achieving a complete response after 6 cycles.
In 2012 was detected swelling in left zygomatic area. Tomographic scanner showed a lytic lesion in left orbit with extension to
the zygomatic bone. Histologic study conﬁrmed plasmacytoma. External beam radiotherapy 30Gy was done at this level with
a partial response. During CT simulation, we detected a new lytic lesion in the thyroid cartilage with associated soft tissue
involvement. For now, is pending perform radiotherapy (20Gy) and subsequent systemic treatment.
Discussion. Plasma cell neoplasms are characterized by neoplastic proliferation of a single clone of plasma cells. They can
present as solitary plasmacytoma (SP), extramedullary plasmacytoma (EP) and multiple myeloma. Solitary plasmacytomas most
frequently occur in bone, involving large bones and axial skeleton. Head and neck location is not frequent. Extramedullary
plasmacytomas (EP) affect submucosal areas and are most often located in head and neck region (80%), mainly in the upper
aerodigestive tract, althought uncommon laryngeal location (<7%). EP can arise in patients with multiple myeloma at any time
during the course of the disease. Plasmacytomas are radiosensitive tumors. Radiotherapy in these tumors may provide a good
local control and symptomatic control of the disease.
Conclusion. Plasmacytomas located in laryngeal area are very uncommon. It is needed and histological conﬁrmation and radio-
therapy is a good treatment option.
http://dx.doi.org/10.1016/j.rpor.2013.03.388
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Background. Medulloblastoma is one of the most common childhood brain malignancies.
Aim. The purpose of this study is to evaluate the tolerability and prognostic factors for toxicity of craniospinal irradiation (CSI)
with helical tomotherapy (HT) in the treatment of medulloblastoma.
Materials and methods. The study was conducted for 19 pediatric patients with primary medulloblastoma (standard risk, N=10;
high risk, N=9) treated with craniospinal HT from May 2007 through December 2010. HT regimens to the neuroaxis included:
23.4Gy at 1.8Gy/fraction (N=10), 36Gy at 1.8Gy/fraction (N=7), and 39Gy bid at 1.3Gy/fraction (N=2). The tumor bed received
54–60Gy at 1.5–1.8Gy/fraction. Spearman’s rank correlation coefﬁcient was used to correlate patient, tumor, and dosimetric
factors with the grade of acute toxicity or the overall survival time.
Results. The median age at diagnosis was 5 years (range, 2–14) and the median follow-up for alive patients (N=14) 40 months
(range, 10–62). Two and three-year overall survival was 75% and 68%, respectively. Only 2 patients had a local failure in the
surgical bed. The most common acute toxicity was hematological (79%), being grade 2 and grade 3 in 4 (21%) and 11 (58%) cases,
respectively. Speciﬁcally, grade 3 acute anemia, neutropenia, and thrombopenia was observed in 5% (N=1), 53% (N=10), and 10%
(N=2), respectively. Therewere no cases of grade 4 acute toxicity. Non grade ≥2 late toxicitieswere observed. Longer time between
diagnosis and radiation therapy associated with shorter overall survival (P=0.03). Older children associated with higher grades of
acute body toxicity (P=0.004), whereas longer radiation treatments associated with higher grades of acute hematological toxicity
(P=0.034).
